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Abstract: Current influenza vaccines offer suboptimal protection and depend on annual reformulation
and yearly administration. Vaccine technology has rapidly advanced during the last decade, facilitating
development of next-generation influenza vaccines that can target a broader range of influenza viruses.
The development and licensure of a universal influenza vaccine could provide a game changing
option for the control of influenza by protecting against all influenza A and B viruses. Here we review
important findings and considerations regarding the development of universal influenza vaccines
and what we can learn from this moving forward with a SARS-CoV-2 vaccine design.
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1. Introduction
An influenza virus infection typically manifests as a fever, sore throat, cough, runny nose, myalgia,
and headaches. People in certain risk groups (the elderly, children <59 months of age, pregnant
women, and individuals with chronic conditions) have a higher chance of developing more severe
illness with complications such as fulminant pneumonia. Seasonal influenza causes around 290,000
to 650,000 respiratory deaths each year [1]. However, this number can increase dramatically when,
at unpredictable intervals, influenza pandemics occur. These global epidemics are characterized
by the emergence of a novel influenza virus to which most humans are immunologically naïve [2].
The emergence of the A/H1N1pdm09 virus (“swine flu”) was the first influenza pandemic of the
21st century. This H1N1 virus has subsequently continued to circulate in the human population as
a seasonal virus, together with influenza A/H3N2 and influenza B (Yamagata-like and Victoria-like)
viruses. The current seasonal influenza vaccines contain strains from each of these viruses. The World
Health Organization (WHO) decides biannually which strains should be included in the vaccine based
on which viruses are most likely to circulate in the upcoming season. Annual seasonal influenza
vaccination remains the most cost-effective measure to reduce burden of the disease. However,
the currently licensed influenza vaccines lack two essential attributes: Firstly, they do not produce
durable protective immunity. Secondly, they do not produce a cross-reactive immune response that
can neutralize diverse influenza virus strains. Cross-reactivity is necessary because of the antigenic
plasticity of the viral membrane protein hemagglutinin (HA), which leads to antigenically drifted
viruses and potential mismatches with the vaccine strains [3]. This shortcoming can be addressed by
developing new vaccines targeting the more antigenically conserved regions of the influenza virus [4].
In order to overcome these barriers, efforts have been made to develop next-generation influenza
vaccines that provide robust, long-lasting protection against diverse influenza A subtypes (Table 1) [5].
The ultimate goal is to develop a “universal” influenza vaccine that covers all influenza A and B viruses.
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Here, we will examine the latest research on next-generation vaccine development and discuss the
prospects and challenges of developing a universal influenza vaccine.
Table 1. Next-generation influenza vaccine attributes: the table is adapted from a report by the Center
for Infectious Disease Research and Policy (CIDRAP) titled “The Compelling Need for Game-Changing
Influenza Vaccines: An Analysis of the Influenza Vaccine Enterprise and Recommendations for the
Future” [6].
Critical Important Desired
Provide protection against all HA
subtypes and at a minimum
protection against H1, H2, H3, H5,
H7 and H9 subtypes.
Provide a decade or more of
protection.
Use manufacturing technology
that can be readily transferred to
developing-world countries.
Provide immunologic protection
for those populations most at risk
for severe disease and increased
mortality
Use inexpensive manufacturing
technology that permits rapid and
highly scalable production,
particularly to address emergence
of a pandemic virus.
Offer heat stability, thereby
eliminating the need to maintain a
cold chain.
Rarely cause adverse events, and
any adverse events are mild and
temporary.
Do not require injection for
administration.
Do not require injection for
administration.
2. Influenza Virus and Target Epitopes
The influenza virus is an enveloped virus with a segmented, negative-sense, single-strand RNA
genome (Figure 1). There are four types of influenza: A, B, C, and D. Influenza A and B are the
only types that cause seasonal epidemics in humans. Influenza A viruses are further subdivided into
subtypes and strains depending on the characteristics of the most abundant surface proteins, HA and
neuraminidase (NA).
HA is a trimeric glycoprotein responsible for the attachment of the virus to the surface of the host
cell by binding to sialic acid receptors. There are 18 subtypes of HA within the influenza A viruses.
These can be divided into two distinct phylogenetic groups: group 1 HA (H1, H2, H5, H6, H8, H9, H11,
H12, H13, H16, H17, and H18) and group 2 HA (H3, H4, H7, H10, H14, and H15). The HA protein
comprises a head domain and a stalk domain, the latter being more antigenically conserved. Antibodies
targeting the HA head domain are usually strain-specific and neutralize influenza viruses by inhibiting
the binding of HA to sialic acid receptors on the surface of the host cell. HA stalk-specific antibodies
can provide heterosubtypic protection by blocking viral fusion with the host cell and by eliminating
infected host cells through antibody-dependent cellular cytotoxicity (ADCC) [7,8]. The stalk-specific
antibodies are broadly cross-reactive within an HA group [9,10].
While HA remains the main target of current inactivated influenza vaccines (IIVs), NA has recently
been recognized as a potential target for universal vaccines [11,12]. NA functions by catalyzing the
cleavage of sialic acids on the surface of an infected cell, leading to the release of newly formed viruses.
Several studies have shown that NA antibody titers correlate with protection in humans [13–15].
NA-specific antibodies function by inhibiting the enzymatic activity of NA and thus preventing the
spread of virions from infected cells. Fc receptor-mediated effector functions such as ADCC have also
been reported for NA antibodies [16,17].
The matrix protein 2 ectodomain (M2e) protein functions by transferring H+ ions through the
viral membrane as the virus is taken up by the endosomes. This leads to conformational changes of
the HA molecule and fusion between the viral membrane and the endosome membrane. As a result,
the viral RNA is released into the cytosol. M2e-specifc antibodies have been shown to be protective
in animal studies, although the exact defense mechanisms are not fully understood. Some studies
have reported Fc receptor (FcR)-mediated effector functions by M2e antibodies [18–20]. Furthermore,
several studies have highlighted the CD4+ and CD8+ T-cell responses induced by M2e [21–24].
Vaccines 2020, 8, 361 3 of 13
Figure 1. An illustration of the influenza virus and the following vaccine targets: the membrane
proteins hemagglutinin (HA), neuraminidase (NA), and matrix protein 2 (M2) and the internal proteins
matrix protein 1 (M1) and nucleoprotein (NP).
T-cell activation also plays an important role in targeting other conserved proteins that are
generally not exposed on the outside of virus particles, such as the nucleoprotein (NP) and matrix
protein 1 (M1) [25]. These proteins are highly conserved between influenza A viruses. Influenza-specific
interferon-secreting T cells, CD4+ T cells, and CD8+ T cells play an important role in recovery from
influenza in humans [26–29].
3. Current Influenza Vaccines
There are currently three types of licensed influenza vaccines: inactivated, live attenuated, and
recombinant HA (Figure 2). Inactivated influenza vaccines (IIVs) are the most commonly used, partly
because of their well-documented safety and low production costs. The IIVs come in three variants:
whole-virion vaccines, split-virion vaccines, and subunit vaccines, which contain purified HA and
NA. IIVs are traditionally produced in embryonated chicken eggs. This egg-based approach has
several drawbacks: Firstly, the production time is relatively long. Consequently, the producers have
to start production months in advance of the flu season, which can lead to mismatches between the
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vaccine strain and the circulating strain [30]. In addition, the prolonged production time becomes a
crucial problem during influenza pandemics, where rapid production and distribution of vaccines
are essential. Another issue with the egg-based approach is the occurrence of egg-adapted mutations
during the production process, which can lower vaccine effectiveness [31,32]. Cell-based IIVs have
been licensed in Europe and the United States as an alternative to the egg-based approach. Another
approach for overcoming egg-based vaccine production is the use of recombinant HA vaccines, which
are based on a protein-expression system using baculoviruses and insect cells [33]. These vaccines
have been licensed in the United States since 2013. However, as with the IIVs, the protection appears
to be strain-specific, with limited immunogenicity.
Figure 2. Influenza vaccine platforms: a diagram of different influenza vaccine platforms. Currently
licensed vaccine formulations include live-attenuated influenza vaccines (A); recombinant HA vaccines
(B); and inactivated-whole (C), split (D), or subunit (E) vaccines. Next-generation vaccine platforms
include virus-like particles (F), peptide-based vaccines (G), nucleic-acid-based vaccines (H), and viral
vector vaccines (I).
Some vaccine formulations include adjuvants in order to improve immunogenicity and vaccine
effectiveness [34]. Adjuvants function by increasing antigen uptake and presentation in the local
draining lymph nodes. During the 2009 H1N1 pandemic, the use of the oil-in-water emulsion (AS03) led
to higher B and CD4 T-cell responses than vaccination with nonadjuvanted pandemic vaccines [35,36].
In contrast to IIVs and recombinant HA vaccines, the live-attenuated influenza vaccines (LAIV)
contain live, cold-adapted viruses that are administered as a nasal spray, leading to a restricted
viral replication in the upper respiratory tract of the recipient [37,38]. The LAIV induces broader
immune response, including T-cell and mucosal immunity, by mimicking natural infection [39–41].
LAIV is currently licensed in North America, Europe, and India. It is generally not recommended for
people younger than 2 years of age due to increased risk of wheezing [42] or for immunosuppressed
individuals who are at greater risk of severe influenza illness as the vaccine may produce higher virus
titers in these individuals, leading to severe side effects.
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4. Next-Generation Vaccine Platforms
Recent scientific advances have made way for novel vaccine approaches, enabling a more targeted
delivery of conserved antigens that can stimulate the innate and adaptive immune systems. Here,
we highlight three vaccine platforms that are being used in the development of next-generation
influenza vaccines (Figure 2).
Virus-like particles (VLPs) have similar morphological and structural features to viruses but lack
the viral genome [43]. They are a useful vaccine component as the immune system recognizes VLPs
similarly to viruses but without the risk of replication and recombination. A variety of immunogens
have been tested on VLPs, including HA, matrix protein 2 (M2), and NA [44–46]. One of the main
barriers to the use of this vaccine construct is the challenge of generating sufficient immunogenicity.
However, the inclusion of adjuvants such as toll-like receptor ligands has led to improved vaccine
effectiveness [47].
In contrast to VLPs, peptide-based vaccines focus on minimal epitopes of the influenza virus,
such as T-cell-inducing NP and M1 peptides [48,49]. However, as with VLP-based vaccines, they often
require the use of adjuvants or particulate carriers for delivery in order to be sufficiently immunogenic.
Nucleic-acid-based vaccines use RNA- or DNA-sequences for the vaccines antigens. This
technology is especially useful in disease outbreaks where rapid vaccine development is needed. Using
self-amplifying mRNA, researchers were able to develop a vaccine candidate for the Influenza A
H7N9 outbreak in China just 8 days after A/Shanghai/2/2013 (H7N9) sequences were released [50].
This vaccine platform could be a viable option in the ongoing efforts to develop a SARS-CoV-2 vaccine.
A phase 1 clinical trial of a DNA vaccine targeting the spike protein of SARS-CoV-1 found that the
vaccine was safe and capable of eliciting neutralizing antibodies and cellular immune responses [51].
Viral vector vaccines use carrier viruses such as modified vaccinia virus Ankara (MVA) or
adenovirus containing genes expressing influenza-proteins of interest [52]. These vaccines allow for
any influenza antigens to be expressed in their native conformation or with modifications, inducing
both humoral and cellular immune responses [53–55]. Most viral vectors are replication-deficient in
mammalian host cells and are therefore safe to use. Issues with pre-existing immunity to some viral
vectors have been reported [56], although other vectors, such as MVA, remain immunogenic despite
the presence of pre-existing immunity.
5. Universal Vaccine Strategies
Influenza vaccines can be divided into two categories based on their immunological features:
(1) vaccines providing sterile immunity by eliciting HA head antibodies that prevent viral attachment
to sialic acid receptors and (2) vaccines that provide infection-permissive immunity by inducing
cellular immunity or broadly reactive antibodies that function in the later stages of the viral life cycle
(Figure 3). Many of the infection-permissive vaccines that are in development will probably not be
universal vaccine candidates as stand-alone vaccines but could be combined with other approaches to
increase immunogenicity.
HA stalk antibodies have emerged as one of the leading strategies in the development of universal
vaccine candidates [57]. Several approaches for avoiding the immunodominant HA head domain
are under development. One strategy is to remove the globular head domain while maintaining the
correct immunogenic conformation of the HA stalk domain [58]. Animal models have shown that
vaccination with these “headless” HA proteins can induce heterosubtypic protection within group 1
HA proteins [59–62]. Other strategies for refocusing the antibody response toward the HA stalk involve
maintaining the full-length HA. Krammer and colleagues have developed a method for directing
the antibody response to the conserved HA stalk domain by sequential vaccination with chimeric
HA proteins consisting of exotic HA head domains to which the recipient is immunologically naïve.
The results of a phase 1 clinical trial (NCT03300050) provide evidence that group 1 chimeric HA-based
vaccines induce high titers of stalk-reactive immunoglobulin G (IgG) that cross-react to other HA
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proteins within the same group [63]. A trivalent vaccine comprising group 1, group 2, and influenza B
virus chimeric constructs could potentially lead to a universal influenza vaccine.
Figure 3. Infection-permissive immunity: T-cell receptors (TCRs) on cytotoxic T lymphocytes (CTLs)
can recognize internal influenza virus proteins (NP and M1) presented by major histocompability
complex (MHC ) class 1 molecules and lyse the infected host cell. Antibodies bound to viral membrane
proteins presented on the surface of the host cell can contribute to clearance of infected cells by activating
natural killer (NK) cells through Fc receptor (FcR) activation in a process known as antibody-dependent,
cell-mediated cytotoxicity (ADCC).
Advances in the development of monoclonal antibodies (mAbs) have shown that there are
cross-reactive epitopes on the HA head domain that can be targeted to give heterosubtypic
protection [64–66]. A new vaccine approach called mosaic HA has been developed to combine
the immunity of conserved epitopes of the HA stalk and head domains. Mosaic HA vaccines are
developed by replacing the immunodominant and strain-specific antigenic sites with sequences from
exotic HA subtypes. Through sequential immunization, the immune response is refocused toward
more cross-reactive immunosubdominant epitopes of the HA stalk and head domains. Cross-reactive
HA stalk- and head-specific antibodies can also be induced by computationally optimized, broadly
reactive antigens (COBRAs). This approach is based on developing novel HA proteins after multiple
rounds of consensus sequence generation from a variety of different HA isolates. Preclinical trials
have demonstrated that COBRA-based vaccines provide protection against multiple influenza viruses
within a subtype in murine and ferret models [67–69].
There has been increased recognition of NA as a target for improved vaccines following the
development of practical assays for measuring antibody responses to NA [11]. Although antibodies
targeting NA can bind to conserved epitopes and provide heterologous protection [16], they are not
really induced by seasonal IIVs. This is mostly due to the amount and stability of the NA in the
vaccines. Enhanced NA–antibody responses can be achieved by delivering NA as a supplement to
current IIVs or vaccinating with recombinant or viral vector NA in addition to the seasonal IIVs [70–74].
M2e has been an attractive target in the development of the future universal influenza vaccine,
as it is highly conserved between influenza viruses [75]. Because of the relatively small size of the
M2e, vaccines usually depend on carrier constructs such as VLPs. Preclinical trials have demonstrated
that M2e antibodies are protective in animal models, and some M2e vaccines have advanced into
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clinical trials [76,77]. While the effectiveness of a stand-alone M2e-based vaccine remains limited,
recent studies have found promising results by combining an M2e-based vaccine (M2e5x VLP) with
other vaccine constructs such as LAIVs [78] and HA VLPs [79].
Most vaccine approaches targeting internal proteins such as M1 and NP involve T-cell activation.
T cells are important during an influenza infection because they limit viral replication and shedding by
clearing influenza-infected cells. An ongoing phase 3 clinical trial (ClinicalTrials.gov: NCT03450915)
is testing a recombinant-peptide based vaccine consisting of conserved epitopes from HA, NP, and
M1 [80]. Other vaccine constructs use viral vectors expressing M1 and NP [54,81]. These have been
shown to induce CD4+ and CD8+ T cells in clinical trials. Selecting the best approach for inducing
T-cell-mediated immunity can be challenging due to the diverse CD4 T-cell repertoire in humans
with different degrees of pre-existing immunity. However, with increasing insights into the quantity,
functionality, and specificity of CD4 T-cell subsets, there is hope that new correlates of protection can
be established in the near future, which would help in selecting the best vaccine candidates for clinical
trials [29,82,83]. Some studies evaluating the T-cell response in various infection models have reported
immunopathology with excessively large CD8 T-cell responses [84,85]. Other studies have reported a
narrowing of T-cell receptors during heterosubtypic challenges [86]. Additional studies that reflect
pathogen encounters in humans are needed in order to select the best candidates for next-generation
T-cell-based vaccines [87].
6. Challenges in the Development of Universal Vaccines
There has been significant progress in the development of novel approaches for universal influenza
vaccines. However, additional efforts are needed in order to translate more of these novel approaches
into products ready for late-stage clinical trials. Selecting the best candidates for clinical trials is a
challenging process for several reasons:
(1) There is no uniform evaluation of novel influenza vaccines in preclinical trials. This is partly
due to the variety of vaccine platforms and targets. In addition, there is no consensus on which
animal model is best suited to accurately reflect human infection [3,88]. This is partly due to the
existence of pre-existing immunity in humans, which is difficult to translate into animal models.
Other host factors to be considered include age, gender, and chronic diseases, which could affect
vaccine efficacy.
(2) There are no established correlates of protection for broadly cross-reactive immune responses
to influenza. Assays measuring non-HA-head immune responses, such as HA stalk antibodies,
NA antibodies, and cellular immunity, are inadequately standardized. Optimization and
standardization of such assays are needed in order to assess the protective immunity contributed
by broadly reactive or universal vaccines.
(3) The funding for universal vaccine development is limited. This leads to down selection of
promising candidates before they advance to clinical trials. Regulatory initiatives are needed
to enhance advocacy for moving from an annually reformulated vaccine to a universal vaccine,
despite the financial risks and inadequate incentives [6].
7. Lessons Learned Moving Forward with a SARS-CoV-2 Vaccine Design
As the search for an appropriate SARS-CoV-2 vaccine continues, comparisons can be drawn to
influenza vaccine development. Some of the next-generation influenza vaccines use vaccine platforms
similar to those used by the SARS-CoV-2 vaccine candidates [89]. Given the urgency of moving forward
with a SARS-CoV-2 vaccine, a nucleic-acid-based vaccine would be a convenient approach in order
to facilitate rapid production. Although this method has been tested for several influenza vaccine
candidates, no DNA or RNA vaccines have yet been licensed for humans. The disadvantages of such
vaccines include limited immunogenicity and reports of increased reactogenicity. Another option
is the use of viral-vector-based vaccines, which have shown promising results against MERS-CoV
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and other emerging viruses [90–92]. Some viral-vector-based vaccines focusing on the S protein of
the SARS-CoV-2 virus are in the preclinical phase. However, it might be years until a nucleic-acid-
or viral-vector-based vaccines are licensed for human use since both of these vaccine platforms are
novel and have not been extensively tested. Other SARS-CoV-2 vaccines that are currently being
tested include recombinant protein vaccines, live-attenuated vaccines, and inactivated vaccines. All of
these platforms can be found among the licensed influenza vaccines, each with their own advantages
and disadvantages.
In the end, a SARS-CoV-2 vaccine or a universal influenza vaccine can only be successful if
implemented effectively [93]. Efforts are needed to improve vaccine uptake by restoring widespread
public confidence in vaccines. This is especially important in a pandemic setting. In addition, as the
2009 influenza A/H1N1 pandemic demonstrated, there will likely be an issue of vaccine availability in
low- and middle-income countries. Therefore, strategies are needed to ensure sufficient and equitable
vaccine distribution to these countries.
8. Conclusions
Encouraging progress has been made in the development of universal influenza vaccines.
Future universal vaccines will likely consist of a combination of different approaches to induce broad
immunity to influenza. Ultimately, the path forward depends on combined action from governments,
industries, and the scientific community.
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